Cue Biopharma Book Value Per Share Growth & History (CUE)
Cue Biopharma's book value per share was $8.21 for fiscal 2025.
View full Cue Biopharma company overviewCue Biopharma annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $8.21 | -$0.29 | −3.36% |
| 2024 | 2024-12-31 | $8.49 | -$15.07 | −63.96% |
| 2023 | 2023-12-31 | $23.56 | -$18.17 | −43.54% |
| 2022 | 2022-12-31 | $41.73 | -$19.28 | −31.60% |
| 2021 | 2021-12-31 | $61.01 | -$16.99 | −21.78% |
| 2020 | 2020-12-31 | $78.00 | $16.35 | +26.52% |
| 2019 | 2019-12-31 | $61.65 | $12.41 | +25.20% |
| 2018 | 2018-12-31 | $49.24 | -$45.74 | −48.16% |
| 2017 | 2017-12-31 | $94.98 | — | — |
Cue Biopharma quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0.44 | -$6.68 | −93.80% |
| Q1 2026 | 2026-03-31 | $6.64 | $3.44 | +107.87% |
| Q4 2025 | 2025-12-31 | $8.21 | -$0.29 | −3.36% |
| Q3 2025 | 2025-09-30 | $5.11 | -$7.53 | −59.58% |
| Q2 2025 | 2025-06-30 | $7.13 | -$6.21 | −46.56% |
| Q1 2025 | 2025-03-31 | $3.19 | -$15.33 | −82.76% |
| Q4 2024 | 2024-12-31 | $8.49 | -$15.07 | −63.96% |
| Q3 2024 | 2024-09-30 | $12.64 | -$15.73 | −55.44% |
| Q2 2024 | 2024-06-30 | $13.34 | -$18.21 | −57.73% |
| Q1 2024 | 2024-03-31 | $18.53 | -$19.70 | −51.54% |
| Q4 2023 | 2023-12-31 | $23.56 | -$18.17 | −43.54% |
| Q3 2023 | 2023-09-30 | $28.37 | -$14.67 | −34.09% |
| Q2 2023 | 2023-06-30 | $31.55 | -$19.12 | −37.73% |
| Q1 2023 | 2023-03-31 | $38.23 | -$18.55 | −32.67% |
| Q4 2022 | 2022-12-31 | $41.73 | -$19.28 | −31.60% |
| Q3 2022 | 2022-09-30 | $43.04 | -$17.72 | −29.17% |
| Q2 2022 | 2022-06-30 | $50.67 | -$18.84 | −27.10% |
| Q1 2022 | 2022-03-31 | $56.77 | -$11.75 | −17.15% |
| Q4 2021 | 2021-12-31 | $61.01 | -$16.99 | −21.78% |
| Q3 2021 | 2021-09-30 | $60.76 | -$26.06 | −30.02% |
| Q2 2021 | 2021-06-30 | $69.50 | -$12.56 | −15.30% |
| Q1 2021 | 2021-03-31 | $68.53 | $17.46 | +34.20% |
| Q4 2020 | 2020-12-31 | $78.00 | $16.35 | +26.52% |
| Q3 2020 | 2020-09-30 | $86.83 | $51.53 | +146.02% |
| Q2 2020 | 2020-06-30 | $82.06 | $53.51 | +187.47% |
| Q1 2020 | 2020-03-31 | $51.06 | $15.36 | +43.01% |
| Q4 2019 | 2019-12-31 | $61.65 | $12.41 | +25.20% |
| Q3 2019 | 2019-09-30 | $35.29 | -$23.42 | −39.89% |
| Q2 2019 | 2019-06-30 | $28.55 | -$44.82 | −61.09% |
| Q1 2019 | 2019-03-31 | $35.71 | -$46.62 | −56.63% |
| Q4 2018 | 2018-12-31 | $49.24 | -$45.74 | −48.16% |
| Q3 2018 | 2018-09-30 | $58.71 | — | — |
| Q2 2018 | 2018-06-30 | $73.37 | — | — |
| Q1 2018 | 2018-03-31 | $82.32 | — | — |
| Q4 2017 | 2017-12-31 | $94.98 | — | — |
Cue Biopharma book value per share trends
Over the last five fiscal years, Cue Biopharma's book value per share decreased from $78.00 to $8.21, a change of -$69.79. The latest reported quarter, Q2 2026, shows $0.44.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Cue Biopharma source filings ↗